Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, Guarini A, Ranieri G, Ditonno P, Berardi S, Caivano A, Basile A, Cascavilla N, Capalbo S, Quarta G, Dammacco F, Ribatti D, Vacca A.
De Luisi A, et al. Among authors: ditonno p.
Clin Cancer Res. 2011 Apr 1;17(7):1935-46. doi: 10.1158/1078-0432.CCR-10-2381. Epub 2011 Feb 9.
Clin Cancer Res. 2011.
PMID: 21307145